

Biosafety Documentation:

Corrected *MHY7 R403Q* *iCell*[®] Products

Donor ID	01178	Genotype	Corrected <i>MHY7 R403Q</i>
Cell Line ID	01178.837	Zygosity	Heterozygous
Donor Sex	Female	OMIM Disease Reference	192600
Starting Material	Blood	OMIM Reference Gene	160760.0001
Age at Collection	50 – 60 years	Catalog #	C1119
Race	Caucasian		
Ethnicity	Unknown		

Cell Source and Biosafety Level Classification

iCell[®] products are human cells differentiated from a master bank of stably induced pluripotent stem (iPS) cells. FUJIFILM Cellular Dynamics, Inc. (FCDI), classifies these cells as Biosafety Level 1 (BSL1) based on the United States Centers for Disease Control and Prevention publication: *Biosafety in Microbiological and Biomedical Laboratories*. Handle the cells according to the biosafety guidelines applicable in your region.

Reprogramming

The iPS cell line was generated from human peripheral blood through ectopic expression of reprogramming factors by episomal transfection.

Following reprogramming, no episomal plasmids were detected by PCR in the iPS cell line.

Engineering

The iPS cell line was engineered to correct the *MYH7 R403Q* mutation resulting in *MYH7 R403R*.

The iPS cell line was further engineered to express blasticidin resistance under the control of a cardiac-specific promoter. A puromycin resistance cassette was also included in the targeting vectors to enable selection of the engineered iPS cell line.

None of the engineering vectors used contain oncogenes.

Infectious Disease Testing

The incoming peripheral blood was tested and non-reactive for HBV, HCV, HIV-1, and HIV-2.